Antitubercular drugs: Advances in nitrogen containing heterocyclic compounds and some other derivatives
Abstract
Mycobacterial infections are infectious diseases. Control of TB is complicated by difficulties in the long-course chemotherapy treatment, the inability to eliminate latent microbes, and the increasing emergence of multidrug resistant strains of M. tuberculosis. New anti-TB drugs are urgently needed, including developments of short-term treatments to minimize the emergence of drug resistance and new drugs to treat multidrug resistant tuberculosis and to eliminate the latent microbes. Many new structural anti-TB agents exhibited promising activities against susceptible and resistant strains of M. tuberculosis.The diarylquinoline with superior anti-tuberculosis activity and encouraging results of nitroimidazopyrans and oxazolidinones have generated considerable excitement. In this review study the efforts to use of drugs for treatment of tuberculosis.
Downloads
References
Asif M. Study of clinically used and recently developed antimycobacterial agents. Orien Pharm & Experi Med, 2012, 12, 15–34.
Zhang Y, Post-Martens K, Denkin S. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today, 2006; 11(1): 21-27.
Hasan S, Daugelat S, Rao PS, Schreiber M. Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput Biol, 2006; 2(6):Epub 2006.
Dye C. Global epidemiology of tuberculosis. Lancet, 2006; 367; 95140: 938-40.
Cole ST, Alzari PM. Towards new tuberculosis drugs. Biochem Soc Transac, 2007; 35 (Part 5): 1321-1324.
Asif M. Development of new antitubercular drugs containing benz-fusedring system. Org Chem: An Indian J, 2013; 9(3): 102-114.
Asif M. Recent efforts for the development of antitubercular drug containing diazine ring. Med Chem, 2012; 2(70): 151-167.
Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Resp and Crit Care Med. 2003; 167(4): 603-662.
Asif M. Mini review on ethmabutol and its some analogues as antitubercular agents. Elixir Pharm, 2012; 53: 11774-11778.
Asif M. Study of currently used antimycobacterials, their analogoues and recently developed agents. Indian drugs. 2012; 49(7): 5-19.
Zhang Y, Amzel LM. Tuberculosis drug targets. Current Drug Targets, 2002; 3(2): 131-154.
Zhang Y. Persistent and dormant tubercle bacilli and latent tuberculosis. Frontiers Bioscience, 2004; 1(9): 1136-1156.
Asif M, Siddiqui AA, Husain A. Quinolone derivatives as antitubercular drugs. Med Chem Res, 2013; 22(3): 1029-1042.
Asif M. A review on potent antitubercular agent isoniazid and its analogues. Inter J Pharm Chem, 2012; 2(4): 110-120.
Eswaran S, Adhikari AV, Kumar R. New 1,3-oxazolo[4,5-c]quinoline derivatives: Synthesis and evaluation of antibacterial and antituberculosis properties. Eur J Med Chem, 2009; 45(3): 957-966.
Eswaran S, Adhikari AV, Chowdhury IH, Pal NK, Thomas K. New quinoline derivatives: synthesis and investigation of antibacterial and antituberculosis properties. Eur J Med Chem, 2010; 45(8): 3374-3383.
Goncalves RS, Kaiser CR, Lourenco MC, de Souza MV, Wardell JL, Wardell SM, da Silva AD. Synthesis and antitubercular activity of new mefloquineoxazolidine derivatives. Eur J Med Chem. 2010; 45(12): 6095-6100.
Mao J, Yuan H, Wang Y, Wan B, Pak D, He R, Franzblau SG. Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs. Bioorg & Med Chem Lett, 2009; 20(3): 1263-1268.
Kini SG, bhat AR, Bryant B, Williamson J, Dayan FE. Synthesis, antitubercular activity and docking study of novel cyclic azole substituted diphenyl ether derivatives. Eur J Med Chem, 2008; 44(2): 492-500.
Yang CL, Tseng CH, Chen YL, Lu CM, Kao CL, Wu MH, Tzeng CC. Identification of benzo-furo[2,3-b]quinoline derivatives as a new class of antituberculosis agents. Eur J Med Chem, 2009, 45(2), 602-607.
Wube AA, Hufner A, Thomaschitz C, Blunder M, Kollroser M, Bauer R, Bucar F. Design, synthesis and antimycobacterial activities of 1-methyl-2-alkenyl-4(1H)-quinolones. Bioorg& Med Chem, 2010; 19(1): 567-579.
De Logu A, Palchykovska LH, Kostina VH, Sanna A, Meleddu R, Chisu L, Alexeeva IV, Shved AD. Novel N-aryl- and N-hetryl phenazine-1-carboxamide as potential targets for the treatment of infections sustained by drug-resistant and multidrug-resistant Mycobacterium tuberculosis. Inter J Antimicrob Agents. 2008; 33(3): 223-229.
Vicente E, Perez-Silanes S, Lima LM, Ancizu S, Burguete A, Solano B, Villar R, Aldana I, Monge A. Selective activity against Mycobacterim tuberculosis of new quinoxaline 1,4-di-N-oxides. Bioorg& Med Chem, 2008; 17(1): 385-389.
Sainath SR, Raghunathan R, Ekambaram R, Raghunathan M. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs. Inter J Antimicrob Agents, 2009; 34(5): 451-453.
Turan-Zitouni G, Ozdemir A, Kaplancikli ZA, Benkli K, Chevallet P, Akalin G. Synthesis and antituberculosis activity of new thiazolylhydrazone derivatives. Eur J Med Chem, 2007; 43(5): 981-985.
Turan-Zitouni G, Kaplancikli ZA, Ozdemir A. Synthesis and antituberculosis activity of some N-pyridyl-N-thiazolylhydrazine derivatives. Eur J Med Chem, 2010; 45(5): 2085-2088.
Sankar C, Pandiarajan K. Synthesis and anti-tubercular and antimicrobial activities of some 2r,4c-diaryl-3-azabicyclo[3.3.1]nonan-9-one N-isonicotinylhydrazone derivatives. Eur J Med Chem, 2010; 45(11): 5480-5485.
Bairwa R, Kakwani M, Tawari NR, Lalchandani J, Ray MK, Rajan MG, Degani MS. Novel molecular hybrids of cinnamic acids ad guanylhydrazones as potential antitubercular agents. Bioorg & Med Chem Lett, 2010; 20(5): 1623-1625.
Correia C, Carvalho MA, Proenca MF. Synthesis and in vitro activity of 6-amino-2,9-diarylpurines for Mycobacterium tuberculosis. Tetrahedron, 2009; 65(34): 6903-6911.
Khoje AD, Kulendrn A, Charnock C, Wan B, Franzblau S, Gundersen LL. Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring. Bioorg& Med Chem, 2010; 18 (20): 7274-7282.
Singh K, Singh K, Wan B, Franzblau S, Chibale K, Balzarini J. Facile transformation of biginelli pyrimidin-2(1H)-ones to pyrimidines. In vitro evaluation as inhibitors of Mycobacterium tuberculosis and modulators of cytostatic activity. Eur J Med Chem, 2011; 46(6): 2290-2294.
Gasse C, Douguet D, Huteau V, Marchal G, Munier-Lehmann H, Pochet S. Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: Synthesis and in vitro anti-mycobacterial activity. Bioorg& Med Chem, 2008; 16(11): 6075-6085.
Odell LR, Nilsson MT, Gising J, Lagerlund O, Muthas D, Nordqvist A, Karlen A, Larhed M. Functionalized 3-amino-imidazol[1,2-a]pyridines: A novel class of drug like Mycobacterium tuberculosis glutamine synthase inhibitors. Bioorg& Med Chem Lett, 2009; 19(16): 4790-4793.
Fassihi A, Azadpour Z, Delbari N, Saghaie L, Memarian HR, Sabet R, Alborzi A, Miri R, Pourabbas B, Mardaneh J, Mousavi P, Moeinifard B, Sadeghi-aliabdi H. Synthesis and antitubercular activity of novel 4-susbtituted imidazolyl-2.6- dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicaroxamides. Eur J Med Chem, 2009; 44(8): 3253-3258.
Mantu D, Luca MC, Moldoveanu C, Zbancioc G, Mangalagiu II. Synthesis and antituberculosis activity of some new pyridazine derivatives. Part II. EurJ Med Chem. 2010; 45(11): 5164-5168.
Güzel O, Karali N, Salman A. Synthesis and antituberculosis activity of 5-methyl/trifluoro methoxy-1H-indole-2,3-dione 3-thiosemicarbazone derivatives. Bioorg& Med Chem, 2008; 16(19): 8976-8987.
Karali N, Gürsoy A, Kandemirli F, Shvets N, Kaynak FB, Özbey, Kovalishyn V, Dimoglo A. Synthesis and structure-antituberculosis activity relationship of 1H-indole-2,3-dione derivatives. Bioorg & Med Chem, 2007; 15(17): 5888-5904.
Kamal A, Shett RVCRNC, Azeeza S, Ahmed SK, Swapna P, Reddy AM, Khan IA, Sharma S, Abdullah ST. Anti-tubercular agents. Part 5: Synthesis and biological evaluation of benzothiadiazine 1,1,-dioxide based congeners. Eur J Med Chem, 2010; 45(10): 4545-4553.
Termentzi A, Khouri I, Gaslonde T, Prado S, Saint-Joanis B, Bardou F, Amanatiadou EP, Vizirianakis I, Kordulakova J, Jackson M, Brisch R, Janin YL, Daffe M, Tillequin F, Michel S. Synthesis, biological activity and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring. Eur J Med Chem, 2010; 45(12): 5833-5847.
Santos JL, Yamasaki PR, Chin CM, Takashi CH, Pavan FR, Leite CQF. Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives. Bioorg& Med Chem, 2009; 17(11): 3795-3799.
Yoya GK, Bedos-Belval F, Constante P, Duran H, Daffe M, Balatas M. Synthesis and evaluation of a novel series of pseudo-cinnamic derivatives as antituberculosis agents. Bioorg & Med Chem Lett, 2008; 19(2): 341- 343.
D´OcaCda R, Coelho T, Marinho TG, Hack CR, Duarte Rda C, da Silva PA, D´Oca MG. Synthesis and antituberculosis activity of new fatty acid amides. Bioorg & Med Chem Lett, 2010; 20(17): 5255-5257.
Palomino JC, Ramos DF, da Silva PA. New anti-tuberculosis drugs: strategies, sources and new molecules. Curr Med Chem, 2009; 16(15): 1898-1904.
Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today, 2008; 13: 1090-1098.
Shi R, Sugawara I. Development of new anti-tuberculosis drug candidates. The Tohoku J Exper Med, 2010; 22(2): 97-106.
Asif M. A Review of antimycobacterial drugs in development. Mini Rev Med Chem, 2012; 12(13): 1404-1418.
Janin YL. Antituberculosis drugs: ten years of research. Bioorg & Med Chem, 2007; 15(7): 2479-2513.
Copyright (c) 2015 Bulletin of Advanced Scientific Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms: a) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
